Enhancing Breast Cancer Monitoring with OkaiDx™
YD Bio Limited, a forward-thinking biotechnology company, is taking significant strides in the realm of post-treatment breast cancer monitoring with its innovative product, OkaiDx™. This research-only blood test utilizes cutting-edge cfDNA methylation technology to provide critical insights into patient care during the monitoring phase after treatment. Its availability through EG Biomed US Inc., a partner with specialized lab certifications, marks a vital step in making advanced cancer monitoring tools accessible to the research community.
Collaboration for Success
With the backing of YD Bio, the commercialization of OkaiDx™ is set to empower researchers, academic institutions, and industry professionals involved in translational studies. This joint effort combines YD Bio's robust biotechnology expertise with EG BioMed's CLIA/CAP-certified lab facilities, ensuring that the test meets the highest standards of accuracy and reliability in the United States.
The Innovation Behind OkaiDx™
The development of OkaiDx™ is the product of international collaboration, drawing on the latest scientific advancements in cancer research. It relies on a sophisticated process that analyzes cfDNA methylation patterns, thereby enabling accurate detection of biomarkers relevant to breast cancer. Peer-reviewed studies from reputable journals have showcased its potential, highlighting an impressive accuracy rate of over 95%, with sensitivity and specificity ratings that confirm its reliability.
What This Means for Patients and Researchers
Currently, OkaiDx™ is designated for research use only and has not received approval or clearance from the U.S. Food and Drug Administration (FDA). Despite this, it represents an invaluable resource for researchers exploring new methodologies for monitoring patients post-treatment. YD Bio envisions a day when this tool could underpin innovative clinical practices aimed at improving patient outcomes.
About YD Bio Limited
Founded with a mission to transform healthcare through innovative diagnostic and therapeutic technologies, YD Bio Limited focuses on high-need areas such as cancer prevention diagnostics and stem cell therapies. Dedicated to enhancing patient care, the company strives for excellence in every aspect of its operations, staying committed to research and development that propels medical science forward.
The Future of Cancer Monitoring
As YD Bio continues to support the commercialization of OkaiDx™, it highlights the company's broader goals of advancing precision medicine and improving patient care. By working closely with EG BioMed, YD Bio is set to facilitate important research that could lay the groundwork for future clinical usage and regulatory approvals. This collaborative effort exemplifies how innovation and teamwork can lead to breakthroughs in cancer monitoring and treatment.
Frequently Asked Questions
What is OkaiDx™ used for?
OkaiDx™ is a cfDNA methylation blood test designed for post-treatment breast cancer monitoring in research settings.
Who is YD Bio Limited?
YD Bio Limited is a biotechnology company focused on cancer diagnostics and therapeutics, committed to improving healthcare through scientific research.
Is OkaiDx™ FDA approved?
No, OkaiDx™ is currently for research use only and is not FDA approved for clinical application.
What are the accuracy rates of OkaiDx™?
Independent assessments have shown that OkaiDx™ features a reported accuracy of 95.1%, with additional metrics showing 89.4% sensitivity and 96.5% specificity.
How can researchers access OkaiDx™?
Researchers can access OkaiDx™ through EG Biomed US Inc.'s CLIA/CAP-certified laboratory facilities for their studies.